Company news: Marksans Pharma

Marksans Pharma on Thursday informed the exchanges that the US FDA has issued Form 483 with eight observations on conclusion of inspection at its Goa facility. The inspection was held during February 26 to March 6. “None of these observations are considered either critical or repetitive in nature. The company is highly confident of closing these expeditiously and remains committed to global standards of quality and compliance,” it said. The site will continue to supply to the US markets all approved ANDAs and the inspection will help it receive pending ANDA approvals too, it further said. Shares of Marksans Pharma slumped 2.60 per cent at ₹26.20 on the NSE.